Infiltrative basal cell carcinoma is an aggressive subtype of the most common skin cancer. Unlike the more typical nodular form, which tends to grow as a well-defined bump, the infiltrative subtype sends thin strands of cancer cells outward into surrounding tissue with poorly defined borders. This makes it harder to see where the tumor ends and healthy skin begins, which complicates treatment and raises the risk of recurrence.
How It Differs From Other Basal Cell Carcinomas
Basal cell carcinoma (BCC) comes in several subtypes, and doctors broadly sort them into two categories: non-aggressive and aggressive. The nodular and superficial forms are considered non-aggressive. They grow relatively slowly, have clear borders, and are usually straightforward to remove. Infiltrative BCC falls into the aggressive category alongside micronodular and sclerosing (morpheaform) subtypes.
What makes the infiltrative type distinct is how it grows under the skin. Under a microscope, the tumor appears as small, angular, spiky nests of cancer cells that extend outward in irregular patterns. Dense collagen surrounds these tumor islands, a feature found in about 96% of infiltrative BCCs compared to only 59% of nodular ones. The edges of the tumor are jagged and poorly defined, which means the cancer often extends further than it appears on the surface.
What It Looks Like on the Skin
Infiltrative BCC can be deceptively subtle. Rather than forming the pearly, raised bump typical of nodular BCC, it often presents as a flat, scar-like area that may look white, yellowish, or waxy. The skin can appear shiny and taut. Because the borders blend into normal skin, it’s easy to mistake for a scar or overlook entirely.
These lesions most commonly appear on sun-exposed areas: the face, ears, neck, scalp, chest, shoulders, and back. Ulceration (an open sore that doesn’t heal) occurs in roughly 42% of cases. The scar-like, flat appearance with poorly defined edges is one of the key warning signs that a BCC may be the infiltrative or morpheaform type rather than a less aggressive form.
Why It’s Considered High Risk
Infiltrative BCC earns its “aggressive” label for several reasons. Its irregular growth pattern means surgeons can’t always tell where the tumor stops, leading to a higher rate of incomplete removal. When surgical margins come back positive (meaning cancer cells are found at the edge of the removed tissue), the risk of the tumor coming back rises significantly. In one study of BCCs with positive margins, the recurrence rate reached 15% among patients who were monitored without further surgery.
The subtype also carries a notable risk of perineural invasion, where cancer cells grow along nerve fibers. This was found in a large proportion of infiltrative BCC cases in research examining this complication. Perineural invasion matters because it gives the tumor a pathway to spread deeper into tissue, increases the chance of local and regional recurrence, and shortens disease-free survival. It’s also associated with larger, deeper tumors. When perineural invasion is present, treatment decisions become more complex and follow-up more intensive.
How It’s Treated
Surgery is the primary treatment for infiltrative BCC, but the approach differs from what’s used for lower-risk subtypes.
Mohs micrographic surgery is generally the preferred option for infiltrative BCC, particularly on the face and other areas where preserving healthy tissue matters. During Mohs, the surgeon removes thin layers of tissue one at a time and examines each layer under a microscope before taking more. This allows precise mapping of the tumor’s irregular borders. Five-year recurrence rates after Mohs surgery for BCC overall are around 3.2%.
Standard surgical excision (cutting out the tumor with a margin of normal skin around it) is another option, with a five-year recurrence rate of about 5.2%. For high-risk lesions like infiltrative BCC, guidelines recommend wider margins than for typical BCCs. While low-risk tumors may need only 3 to 4 millimeters of surrounding tissue, high-risk subtypes call for 5 to 10 millimeters according to European guidelines, or 4 to 6 millimeters per U.S. recommendations. For tumors larger than 2 centimeters, a 5-millimeter margin is generally considered the minimum for achieving clear edges.
The wider margins reflect the reality that infiltrative BCC extends beyond what’s visible. Even with appropriate margins, the rate of positive (incomplete) surgical margins for BCC overall is about 12%, which underscores why careful pathology review after surgery is essential for this subtype.
What Happens After Surgery
Close follow-up is particularly important with infiltrative BCC. Because of the higher recurrence risk, your dermatologist will typically schedule regular skin checks for several years after treatment. Recurrences tend to appear at the original site, so monitoring the surgical scar for any changes is part of routine follow-up.
If the pathology report shows positive margins after a standard excision, the decision between re-excision and watchful monitoring depends on the location, the patient’s health, and how much tissue was involved. Re-excision doesn’t guarantee a clean outcome. In one study, half of patients who underwent early re-excision after positive margins still experienced recurrence, though this likely reflects the difficulty of fully clearing aggressive subtypes rather than a failure of the approach itself.
Having one infiltrative BCC also increases your overall risk of developing additional basal cell carcinomas in the future, whether the same subtype or a different one. Sun protection and regular full-body skin exams become a long-term routine rather than a one-time concern.